Glioblastoma (GBM) is one of the most common malignancies of the central nervous system (CNS), and despite aggressive combinatory treatment, including maximal surgical resection, radiotherapy, and adjuvant chemotherapy, prognosis remains dismal. GBM in particular is characterized by extensive tumor heterogeneity as well as cancer cell plasticity and the presence of cancer stem cells. 1,2 These multifaceted factors contribute to the ability of GBM to evade almost any treatment strategy. 1, 2 Understanding the complex biology of GBM in its physiological environment is a key for the development of new therapeutic options, and improvement of currently available animal models is a crucial prerequisite. 3 Xenograft models, which are based on the orthotopic transplantation of either patient-derived glioblastoma cells or fresh brain tumor biopsy spheroids into immunedeficient rodents, resemble closely the genetic and phenotypic heterogeneity of the original patient tumor. 
to their clinical relevance, xenograft models remain the gold standard for understanding the biology of GBM. 3 However, while recapitulating human gliomablastoma sufficiently well, orthotopic xenografts in rodents are technically challenging. In addition, ethical and financial constraints make them unsuitable for use in drug screening and profiling projects.
During the last decade, the zebrafish (Danio rerio) has been characterized as a powerful and clinically relevant model for human diseases, including cancer. [4] [5] [6] Besides its ex utero development, small size, high fecundity, and cost-efficient husbandry, the absence of a functional adaptive immune system until embryonic day 21 makes it an ideal animal model for xenotransplantation. Furthermore, the zebrafish is highly suitable for large-scale drug discovery projects, and its predictive capacity has already been exploited in various high-throughput screens. 7 Orthotopic xenograft models of GBM in zebrafish have been reported by several groups 8, 9 and recent studies highlighted their extraordinary recapitulative potential and clinical relevance. 10, 11 However, since intracranial transplantation of GBM material into single zebrafish embryos is technically challenging and time-consuming, the use of zebrafish to understand the complex biology of GBM and to facilitate high-throughput screens for candidate therapies is currently limited. A novel method allowing for easy, fast, and automatable orthotopic injection of GBM material into zebrafish embryos would considerably help not only to understand GBM biology but also to develop, characterize, and verify novel treatment options.
Materials and Methods

Zebrafish Maintenance and Transgenic Strains
The zebrafish tupfel longfin, fli1a:EGFP, 12 HuC (elavl3):GFP, 13 mpeg1:mCherry, 14 and the Zebrabow 15 strains were used throughout this study and raised and staged according to standard conditions. 16 Transplanted zebrafish embryos were kept at 33°C. As described before, 17, 18 neither embryo growth/ viability nor GBM proliferation ( Supplementary Fig. S1 ) was affected. 17, 18 All experimental protocols were performed in accordance with the national ethical guidelines and regulations (N207/14).
Cryosections and Immunocytochemistry
Transplanted zebrafish embryos were prepared for cryosections as described previously 19 and sections were stained with anti-Ki67 (#P6834, Sigma) and anti-green fluorescent protein (GFP) antibodies (#SC8334, Santa Cruz) together with an anti-mouse/Alexa Fluor 488 secondary antibody using routine protocols. Images were taken with a Zeiss LSM 700 confocal microscope.
Cell Culture
All cells have been growing at 37°C in a humidified atmosphere (95% humidity) with 5% CO 2 . The GBM cell line U343-MGA-GFP 20 as well as the primary GBM culture #18 21 have been propagated in Minimum Essential Medium (Gibco) containing 2 mM glutamine (Gibco). Primary GBM cultures #3101 22 and #3204 22 have been propagated as stated in the reference. SW620 cells have been propagated following the suggestions of the American Type Culture Collection. All cells have been dissociated with Accutase (Sigma) at subconfluency. For details on generation and authentication of patient-derived GBM cell lines used in this study, see the respective references. Generation of GBM#18 cells expressing an octamer-binding transcription factor 4 (Oct4)/sex determining region Y-box 2 (Sox2) reporter has been described before. 23 GBM cells stably expressing tdTomato or luciferase were generated with a lentivirus-based approach using the vector #32904 or #17477 (Addgene). Regular mycoplasma tests have been performed in all cell cultures using Mycoalert (#LT07, Lonza).
Transplantation of Glioblastoma Cultures and Treatment
Glioblastoma cultures were maintained as stated above and transferred to complete neural stem cell medium 7 days before transplantation. All cell cultures were prepared for injection as previously described. 25 Briefly, cells were washed with phosphate buffered saline (PBS) and labeled with DiI, a fluorescent dye (1:250 in PBS, #V22885, Molecular Probes) for 15 min, followed by several washing steps using PBS to remove residual dye particles. Subsequently, cells were harvested, passed over a 20 µM nylon mesh, and resuspended in medium containing 2% polyvinylpyrrolidone (Sigma) to avoid clogging of the
Importance of the study
The development of novel drugs fighting GBM is challenging, as no orthotopic animal model exists which can readily be implemented in large-scale drug discovery screens. The zebrafish is a clinically relevant model for human malignancies, and orthotopic transplantation of GBM material was found to faithfully recapitulate the human disease. However, none of the currently available transplantation procedures in zebrafish can be used in high-throughput screens, as the injection process is time-consuming and technically challenging. We have refined existing orthotopic zebrafish models and developed an approach which allows for transplantation of thousands of embryos per hour. This model can facilitate automated drug discovery and profiling as well as help to identify novel candidate drugs against GBM.
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micro-injection capillary. Directly before transplantation, cells were spun down and medium was almost entirely removed. The cell suspension was loaded in nonfilament microcapillaries (World Precision Instruments) and approximately 100 tumor cells were injected into blastula-stage zebrafish embryos which have been immobilized in an agarose mold. After injection, embryos were screened for successful transplantation, transferred into a 10 cm dish, and incubated at 33°C for 24 hours before analysis or subsequent treatment. For treatment, embryos were distributed to 6-well plates (20 embryos/well) in a total volume of 3 mL E3 medium containing 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid). Tyrosine kinase inhibitors (TKIs; dissolved in dimethyl sulfoxide [DMSO] for 10 mM) were added directly to the medium to a final concentration of 20 µM. DMSO was used as control. For documentation, embryos were mounted in 1% methyl cellulose (Sigma) and pictures were taken with a Leica MZ16 microscope equipped with a Leica DCF3000FX camera.
Time-Lapse Confocal Imaging
Transplanted embryos were anesthetized with MS222 (Sigma), mounted in low-melting agarose (Thermo Scientific), and covered in E3 medium. Imaging was performed using an upright Leica TCS SP8 MP microscope, equipped with a 10x/0.3 numerical aperture (NA) long working distance apochromat immersion lens (Leica, 506142). The fluorophores were excited with 488-nm and 552-nm lasers, and the images were registered in bidirectional nonresonant scanning mode. Stacks were captured at 12 min intervals with a step size of 10 µm, for 24 hours, using the minimal necessary laser power (optical power meter, Thorlabs, PM100D). Image processing (denoising, enhancing signal intensity) and visualization were performed with Imaris Software (Bitplane) and ImageJ (NIH).
Luminescence Measurement
Single zebrafish embryos were lysed for 15 min in 96-well plates (10% glycerol, 1% Triton-X100, 1 mM dithiothreitol [DTT], pH 7.8) followed by incubation with an equal amount of substrate solution (1 mM DTT, 1 mM ATP, 0.3 mg/mL D-luciferin, pH 7.8) for 5 min and subsequent luminescence measurement (Hidex Sense).
Light-Sheet Microscopy
Twenty-four hours post fertilization (hpf), embryos were mounted in a glass capillary containing 1% low melt agarose and, following polymerization, were extruded into an imaging chamber containing E3 medium supplemented with MS222. Time-lapse images were acquired on a Zeiss Lightsheet Z.1 using a 10x detection objective (W-PlanApochromat-0.5NA) and 10x illumination objectives (lightsheet fluorescence microscopy, 0.2NA). Samples were illuminated from one or both directions and Z-stacks were acquired every 15 min using a 1x optical zoom, 6.4 µm lightsheet thickness, and 1.8 µm Z-interval. The Contour Surface tool in Imaris 8.4.1 (Bitplane) was used to measure tumor volume at each time point. Max intensity projections were generated and sample drift was corrected for using a rigid body transformation in the StackReg plugin of ImageJ.
Statistical Analysis
All experiments were performed at minimum in triplicates. The results are presented as mean ± SD. Statistical significance was determined using the 2-tailed Student's t-test (GraphPad Prism v6). The following P-values were considered significant: **P < 0.01; ***P < 0.001; ****P < 0.0001.
Results
Based on fate-map analysis and the observation that early zebrafish embryos could potentially provide lineage-specific trophic support to human cells, 24 we reasoned that human brain cancer cells injected into zebrafish blastula stages might migrate into CNS structures of the developing zebrafish embryo (Fig. 1A) . To test our hypothesis, we transplanted a patient-derived GBM culture (GBM#18) 21 into embryos at the blastula stage (3.5 hpf) and found that within 24 hours post transplantation (hpt) 70 ± 7.9% of 99 injected embryos developed a congregated tumor in the CNS (Fig. 1C) . Intrigued, we transplanted those human GBM cells into transgenic zebrafish embryos expressing a pan-neuronal marker (elavl3:GFP) and followed their migration by time-lapse confocal microscopy. This real-time analysis revealed that the transplanted cells coalesce in the anterior part of the developing zebrafish embryo before the specification of neurons and that the human GBM cells remained in the neurogenic region of the developing zebrafish embryo during brain formation (see Fig. 1B , Supplementary movie S1). In order to elucidate if this migratory behavior might be a general phenomenon of GBM cultures, we continued transplanting an established GBM culture, U343-MGA-GFP, as well as primary GBM material, GBM#3101 15 and #3024, 15 into blastula-stage zebrafish embryos. Our analysis showed that at 24 hpf, 67.2 ± 5.9% of embryos injected with U343-MGA-GFP (n = 444), 88.3 ± 1.2 of embryos transplanted with GBM#3101 (n = 178), and 90.5 ± 0.7% of embryos transplanted with GBM#3024 (n = 154) suffered from an orthotopic intracranial tumor ( Fig. 2A, B) . We continued by investigating if the transplantation site within the blastoderm of zebrafish embryos could influence the migratory behavior of GBM cells and transplanted GBM#18 cells either apically or basically into the blastoderm. At 24 hours after apical injection into blastula embryos, 74 ± 10% of tumors were located in the fore/midbrain, whereas no tumor was found in the hindbrain and 25 ± 10% of tumors were located in the tail (n = 26). One day after basal injection into blastula embryos, 73 ± 2.5% of tumors were established in the fore/midbrain, 3 ± 2.5% were found in the hindbrain, and 25 ± 10% were located in the tail (n = 40) (Fig. 2C) . Besides, we transplanted SW620 colon cancer cells into blastula-stage embryos, with only 7 ± 3% of intracranial tumors being established until 24 hpf (n = 123) ( Fig. 2A, B) . Transplantation at blastula stage was tolerated by the embryos and at 24 hpf, we found 90 ± 3.0% of U343-MGA-GFP, 74 ± 8.7% of GBM#3101, 65.5 ± 0.7% of GBM#3024, and 81 ± 23% of SW620 transplanted embryos alive (Fig. 2D) .
After confirming the robustness of our novel transplantation procedure, we analyzed the xenotransplants by light-sheet microscopy and observed that U343-MGA cells extended tumor microtubules into the host CNS 2 days after transplantation, reminiscent of the human disease (Fig. 3A, Supplementary movie S2) . Real-time imaging revealed that this network of protrusions starts to form as early as 24 hpt (Fig. 3B, C, Supplementary movies S3, S4) . Intriguingly, the tumor microtubule network continued to grow in complexity until the humane endpoint of the experiment was reached at 6 days post fertilization (Fig. 3E, F and Supplementary movie S5). Simultaneously with sending out protrusions, the volume of U343-MGA transplants increased by ~20% within 24 hours (Fig. 3D) . Besides, orthotopically transplanted GBM#18 as well as primary GBM material #3024 also actively proliferated in zebrafish embryos, as shown with anti-Ki67 staining (demarking proliferating cells) on cryosections (Fig. 4A, B) . Moreover, transplantation into fli:EGFP embryos with a fluorescent blood vessel system followed by cryosectioning revealed ongoing tumor vascularization (Fig. 4A, B) . Active tumor vascularization was also confirmed by light-sheet real-time imaging of fli:EGFP embryos transplanted with GBM#18 cells expressing a red fluorescent protein (Fig. 4F, Supplementary movie S6) . Besides active tumor angiogenesis, which is a prerequisite for a clinically relevant GBM animal model, the interaction of GBM with host macrophages/microglia plays a crucial role for tumor aggressiveness and infiltration. 25 In order to detect a possible interaction, we orthotopically transplanted U343-MGA into mpeg1:mCherry transgenic zebrafish that express a red fluorescent protein in macrophages/ microglia. 14 Applying light-sheet microscopy, we could confirm a tight interaction of host macrophages/microglia with the U343-MGA transplant; single transplanted GBM cells were also engulfed and resorbed (Fig. 4C,  Supplementary movie S7) . Besides the interaction with macrophages/microglia, the aggressiveness of GBM is also driven by the presence of cancer initiating cells which can be identified by Oct4/Sox2 expression. 26 Transplantation of GBM#18 cells expressing GFP under the control of the Oct4/Sox2 recognition site revealed that cancer initiating cells persist in the zebrafish embryo over time (Fig. 4E) .
After a thorough characterization of our improved orthotopic GBM animal model, we sought to assess the antitumor activity of small molecules using our platform. Since neither U343-MGA nor GBM#18 is sensitive to today's standard-care temozolomide, 23 we tested several TKIs which are in clinical trials to treat astrocytoma, including glioblastoma. Zebrafish embryos were 
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transplanted with luciferase expressing U343-MGA or GBM#18 cells and from 24 hpt on exposed to the TKI erlotinib, R-crizotinib, gefitinib, or afatinib for 2 days. Because the tumor cells were engineered to express luciferase, single embryos could be transferred to 96-well plates for quantification of the bioluminescence of remaining tumor. We found erlotinib to reduce the tumor burden of U343-MGA cells most significantly-all other tested TKIs had only limited albeit significant effect (Fig. 4G) . We could also measure a significant reduction of tumor burden, despite being generally less sensitive to the TKIs, in all groups of the more aggressive primary GBM culture #18 (Fig. 4G ).
Discussion
Glioblastoma is one of the most intractable forms of cancer. Its complex biology as well as the lack of predictive animal models which can be used in high-throughput screens severely hamper the development of new treatments. 3 Although many orthotopic and clinically relevant rodent models have provided invaluable insights, they remain technically challenging, ethically problematic, and expensive. Therefore, orthotopic rodent models can neither be easily implemented in research laboratories to address the complex biology of GBM nor be used in high-throughput drug discovery screens, leaving academic and commercial drug exploratory research without any clinically relevant, orthotopic GBM model for large-scale screening and high-throughput profiling of small molecules. The zebrafish is a well-established and clinically relevant model for cancer 4, 5, 27 and suitable for automated high-throughput screens, since embryos can be raised, treated, and screened in 96-well plate formats, and robotics for automated zebrafish embryo handling are commercially available. 7, 28, 29 Orthotopic transplantation procedures of GBM material into embryonic zebrafish have been developed during the last years and their extraordinary disease recapitulating potential described in detail. 10, 11, [30] [31] [32] However, all currently published orthotopic zebrafish models depend on direct intracranial injection, which requires sedation and precise positioning of embryonic zebrafish, and the transplantation process remains slow and technically challenging. Therefore, those models, although clinically relevant, cannot readily be implemented in high-throughput screens to profile novel candidate compounds.
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Here, we present a substantial improvement of available orthotopic GBM animal models. Instead of transplanting directly into the cranium of embryonic zebrafish, we injected GBM cells at 3.5 hpf into blastula-stage embryos. At this stage, hundreds of embryos can easily be lined up in agarose molds and transplanted quickly; neither sedation nor precise orientation is required compared with all previously published orthotopic animal models. Intriguingly all our analyzed GBM cultures, both established cell lines as well as primary patient-derived material, migrated from their injection site within the blastoderm into the CNS and established a congregated, orthotopic tumor within 24 hpt, indicating a general migration capacity of GBM material. We did not observe that the transplantation site within the blastoderm influenced their migration into the CNS, likely because ectoderm precursor cells are found at all latitudes in the blastoderm fate map. 33 Homing to the natural microenvironment of human cells transplanted into blastula embryos has been observed before, and it was postulated that the early zebrafish embryo contains homing cues and trophic support which can be interpreted by human cells. 24 Interestingly, during preparation of our tumor cells for transplantation we observed that dissociating GBM cultures using trypsin, an enzyme which degrades surface molecules, significantly reduced their CNS homing capacity compared with dissociation with Accutase, which is a much milder dissociation reagent (Supplementary Figure. S2 ), indicating that indeed surface molecules of the transplanted cells are involved in the perception of homing cues.
Both tumor volume measurements and immunohistochemical analysis confirmed that GBM cell lines and primary GBM cultures proliferate in the zebrafish. Furthermore, actively ongoing tumor vascularization as well as the tight interaction of host macrophages/microglia with the xenotransplants imply a high clinical relevance of our animal model. 25, 34 During recent years it has been described that astrocytomas, including GBM, establish tumor microtubule networks which facilitate tumor invasion and proliferation and that those interconnections might be a new target for GBM therapy. 35 Intriguingly, we observed similar microtubule structures as early as 24 hpt which were growing in length and complexity until the humane endpoint was reached, confirming again the clinical relevance of our improved orthotopic animal model.
The fast orthotopic transplantation process described here allows the model to be used in compound screens. As neither U343-MGA nor GBM#18 responds to standardcare temozolomide, 23 we tested different TKIs which are in clinical trials. After only 2 days of treatment we found erlotinib to have superior antitumor effects compared with the other tested TKIs on U343-MGA cells. In line with our observations, it has been published that erlotinib has the best blood-brain barrier passage and lowest brain efflux rate of our tested TKIs [36] [37] [38] [39] in humans and that it exhibits the highest response rate in patients, 40 indicating that our model can faithfully recapitulate its pharmacoactivity in vivo. Besides, it has been published before that orthotopically transplanted mouse brain tumors into zebrafish retain their histological and pharmacological profile for erlotinib. 10 In contrast to U343-MGA, erlotinib and the other TKIs had only limited but significant effect on the primary GBM#18 transplants. Although it has been published that GBM#18 is highly resistant to imatinib, another TKI, 21 
further sequencing of the cells to identify potential resistance mechanisms would be needed to fully understand the pharmacological profile.
In summary, we provide evidence that our improved orthotopic animal model not only faithfully recapitulates the clinical characteristics of the tumor but could also be easily implemented in drug screens. Importantly, a robust and predictive drug screen can be done in as few as 3 days (Fig. 5) . Additionally, as the whole experimental pipeline, including transplantation, drug exposure, and evaluation, can be performed in zebrafish embryos younger than 5 days, no ethical permit is required in most countries and therefore our model complies with the 3R guidelines (replace/reduce/refine). Lastly, it is tempting to speculate that our improved in vivo model could, due to its robustness, be used to transplant freshly excised tumor specimen from patients in order to rapidly evaluate the best option for GBM therapy.
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